Education
About Us
Working with TipRanks
Follow Us
Integra Lifesciences Holdings Corp. (IART)
NASDAQ:IART
IART Stock Chart & Stats
Day’s Range― - ―
52-Week Range$16.81 - $36.80
Previous CloseN/A
Volume73.30K
Average Volume (3M)682.55K
Market Cap
$1.69B
Enterprise Value$3.10B
Total Cash (Recent Filing)$591.91M
Total Debt (Recent Filing)$186.38M
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Apr 23, 2025EPS Estimate
0.43Last Dividend Ex-Date
Jul 02, 2015Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding77,218,920
10 Day Avg. Volume1,025,836
30 Day Avg. Volume682,548
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.05
Price to Cash Flow (P/CF)8.30
P/FCF Ratio37.80
Enterprise Value/Market Cap1.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.52
Enterprise Value/Ebitda13.22
Forecast
1Y Price Target
$25.33Price Target Upside15.82% Upside
Rating ConsensusHold
Number of Analyst Covering6
---
Integra Lifesciences News
PremiumCompany Announcements
Integra LifeSciences Reports Mixed Earnings Amid Challenges
---
Bulls Say, Bears Say
Bulls Say
LeadershipThe new CEO, Mojdeh Poul, brings over 30 years of MedTech experience, which is seen as timely as the company works to resolve its challenges.
Strategic InitiativesManagement has implemented a Compliance Master Plan and partnered with third-party consulting firms to address quality issues, showing proactive steps towards improvement.
Bears Say
Financial GuidanceFY25 revenue guidance is expected to be below prior Street expectations, which could indicate limited growth potential.
Operational ChallengesThe company is approaching FY25 cautiously with additional shipping holds due to quality remediation efforts, indicating ongoing operational challenges.
---
Ownership Overview
3.19% Insiders
31.05% Mutual Funds
20.01% Other Institutional Investors
17.81% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IART FAQ
What was Integra Lifesciences Holdings Corp.’s price range in the past 12 months?
Integra Lifesciences Holdings Corp. lowest stock price was $16.80 and its highest was $36.80 in the past 12 months.
What is Integra Lifesciences Holdings Corp.’s market cap?
Integra Lifesciences Holdings Corp.’s market cap is $1.69B.
When is Integra Lifesciences Holdings Corp.’s upcoming earnings report date?
Integra Lifesciences Holdings Corp.’s upcoming earnings report date is Apr 23, 2025 which is in 47 days.
How were Integra Lifesciences Holdings Corp.’s earnings last quarter?
Integra Lifesciences Holdings Corp. released its earnings results on Feb 25, 2025. The company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.854 by $0.116.
Is Integra Lifesciences Holdings Corp. overvalued?
According to Wall Street analysts Integra Lifesciences Holdings Corp.’s price is currently Undervalued.
Does Integra Lifesciences Holdings Corp. pay dividends?
Integra Lifesciences Holdings Corp. pays a Notavailable dividend of $3.184 which represents an annual dividend yield of N/A. See more information on Integra Lifesciences Holdings Corp. dividends here
What is Integra Lifesciences Holdings Corp.’s EPS estimate?
Integra Lifesciences Holdings Corp.’s EPS estimate is 0.43.
How many shares outstanding does Integra Lifesciences Holdings Corp. have?
Integra Lifesciences Holdings Corp. has 77,218,920 shares outstanding.
What happened to Integra Lifesciences Holdings Corp.’s price movement after its last earnings report?
Integra Lifesciences Holdings Corp. reported an EPS of $0.97 in its last earnings report, beating expectations of $0.854. Following the earnings report the stock price went up 12.109%.
Which hedge fund is a major shareholder of Integra Lifesciences Holdings Corp.?
Currently, no hedge funds are holding shares in IART
---
Integra Lifesciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$25.33 (15.82% Upside)
$25.33 (15.82% Upside)
Blogger Sentiment
Bullish
IART Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 4.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $100.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-39.02%
12-Months-Change
Fundamentals
Return on Equity
-0.44%
Trailing 12-Months
Asset Growth
6.75%
Trailing 12-Months
Company Description
Integra Lifesciences Holdings Corp.
Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical, and Orthopedics and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company's neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices. The Orthopedics and Tissue Technologies segment includes offerings such as skin and wound repair, bone and joint fixation implants in the upper and lower extremities, bone grafts, and nerve and tendon repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.
---
IART Company Deck
---
IART Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth and EPS performance. However, significant operational challenges and quality-related issues impacted organic growth and margins. The company is focused on executing its compliance master plan and improving manufacturing capacity. Guidance for the first quarter of 2025 indicates potential continued challenges, but strategic initiatives show promise for future growth.Read More>---
IART Stock 12 Month Forecast
Average Price Target
$25.33
▲(15.82% Upside)
Technical Analysis
Best Analysts Covering IART
1 Year
1 Year Success Rate
9/12 ratings generated profit
1 Year Average Return
+17.21%
reiterated a sell rating 10 days ago
Copying Craig Bijou's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +17.21% per trade.
---